Pearl Therapeutics is rapidly developing a portfolio of products that offer distinct clinical benefits to patients in the most widely used inhaled drug delivery format, the metered dose inhaler (MDI). Our hydrofluoroalkane (HFA) MDI-based products use proprietary engineered particle technology to achieve unprecedented performance and reliability from an MDI, and are intended to treat patients at all stages of chronic obstructive pulmonary disease (COPD) and asthma. Pearl has successfully formulated a majority of the bronchodilators and inhaled steroids commonly used in the respiratory space, along with their combinations, thereby demonstrating the versatility of its platform. The company is focused on developing high value combination products for patients across all stages of disease, with our lead product a twice-daily bronchodilator LAMA/LABA combination for the treatment of COPD.

Pipeline